Bio

Neev Patel, MD, is a fellow in Critical Care Medicine at Stanford University School of Medicine, where he also completed clinical fellowship training in Nephrology. His work sits at the intersection of critical care nephrology and point-of-care ultrasound, using bedside echocardiography to characterize hemodynamics in acute kidney injury, cardiorenal syndrome, and hepatorenal syndrome.

His current research examines echocardiographic predictors of vasoconstrictor response in hepatorenal syndrome, work he leads for the echocardiography and cirrhotic cardiomyopathy working group of the multi-center HRS Harmony Consortium, and the use of left ventricular velocity-time integral as a portable measure of stroke volume in the Project Baseline and WASE cohorts.

He completed internal medicine residency at LSU Health Shreveport, graduating with honors in the Clinician Educator Track, and earned his MBBS with distinction from B. J. Medical College in Ahmedabad, India. He is board certified in internal medicine and holds testamur status in critical care echocardiography (CCEeXAM).

He is an active medical educator. He founded pocuspal.com, an open-access point-of-care ultrasound teaching site, and built crrtcalc.com, a sodium simulator that models serum sodium trajectories during continuous renal replacement therapy to guide safe correction in neuro-ICU patients. He contributes to the Free Open Access Medical Education (FOAMed) community and teaches on X at x.com/NeevP37.

Clinical Focus

  • Fellow
  • Critical Care Nephrology
  • Point-of-Care Ultrasound
  • Critical Care Echocardiography
  • Acute Kidney Injury
  • Cardiorenal Syndrome
  • Hepatorenal Syndrome
  • Continuous Renal Replacement Therapy

Honors & Awards

  • Graduated with Honors, Clinician Educator Track, Louisiana State University Health Sciences Center, Shreveport, LA (2024)
  • Best Oral Presentation, Internal Medicine Annual Research Day, Louisiana State University Health Sciences Center, Shreveport, LA (2023)
  • MBBS awarded with Distinction, Gujarat University, Ahmedabad, India (2020)

Boards, Advisory Committees, Professional Organizations

  • Member, American College of Physicians (ACP)
  • Member, American Society of Nephrology (ASN)
  • Member, American College of Chest Physicians (CHEST)

Professional Education

  • Clinical Fellowship, Stanford University School of Medicine / Stanford Health Care, Palo Alto, CA, Critical Care Medicine (in progress)
  • Clinical Fellowship, Stanford University School of Medicine / Stanford Health Care, Palo Alto, CA, Nephrology (2026)
  • Residency, Louisiana State University Health Sciences Center, Shreveport, LA, Internal Medicine (Clinician Educator Track, graduated with honors) (2024)
  • MBBS, B. J. Medical College, Gujarat University, Ahmedabad, India, Medicine and Surgery (2020)
  • Testamur, CCEeXAM, National Board of Echocardiography, Critical Care Echocardiography (2025)
  • Board Certification, American Board of Internal Medicine, Internal Medicine (2024)
  • Certification, Louisiana State University Health Sciences Center, Shreveport, LA, Point-of-Care Ultrasound (POCUS) (2024)

Community and International Work

  • AAMC Visiting Student Learning Opportunities (VSLO) Program Enrollment, Ahmedabad, Gujarat, India

    Topic

    VSLO Representative

    Partnering Organization(s)

    B. J. Medical College, Ahmedabad, India

    Location

    International

    Ongoing Project

    No

    Opportunities for Student Involvement

    Yes

Personal Interests

Tennis, hiking, surfing, photography, and backpacking.

Additional Info

Links

Current Research and Scholarly Interests

This research uses point-of-care and comprehensive echocardiography to answer hemodynamic questions at the bedside in critically ill patients with kidney disease.

Hepatorenal syndrome and cirrhotic cardiomyopathy. The echocardiography and cirrhotic cardiomyopathy working group he leads within the HRS Harmony Consortium is harmonizing data across Stanford, Vanderbilt University, and Virginia Commonwealth University to identify predictors of terlipressin and norepinephrine response. A companion single-center analysis examines how cirrhotic cardiomyopathy shapes that response.

Portable measures of stroke volume. Using healthy-adult data from Project Baseline and the World Alliance Societies of Echocardiography (WASE) study, this work compares linear and allometric scaling of the left ventricular velocity-time integral as a surrogate for stroke volume across body sizes, with the goal of making serial hemodynamic assessment practical outside the echocardiography laboratory.

Right ventricular assessment in pulmonary hypertension. A Stanford collaboration compares M-mode and tissue Doppler-derived TAPSE for classification of pulmonary hypertension using CART analysis, quantile regression, and ROC comparisons across normal and pulmonary hypertension cohorts.

Acute kidney injury in neurocritical care. An invited review in progress addresses the pathophysiology, hemodynamics, and renal replacement therapy considerations of acute kidney injury in severe traumatic brain injury, subarachnoid hemorrhage, and post-cardiac-arrest populations - the same questions that motivated crrtcalc.com, an open-access simulator of serum sodium trajectories during continuous renal replacement therapy.

Current Clinical Interests

  • POCUS
  • AKI in ICU
  • Cardiorenal medicine
  • Critical Care Nephrology
  • Echocardiography
  • Critical Care Echocardiography
  • Hepatorenal Syndrome
  • Continuous Renal Replacement Therapy

Clinical work centers on critically ill patients with acute kidney injury and complex cardiorenal and hepatorenal physiology, using point-of-care and critical care echocardiography at the bedside to guide volume, vasoconstrictor, and renal replacement therapy decisions. Practice spans the intensive care unit and the inpatient nephrology consult service, with procedural experience in continuous renal replacement therapy, dialysis catheter placement, and renal biopsy.

Research Projects

  • Management of Acute Kidney Injury in Severe Acute Brain Injury (Invited Review)

    Invited review of the pathophysiology, hemodynamics, and renal replacement therapy considerations of acute kidney injury in severe traumatic brain injury, subarachnoid hemorrhage, and post-cardiac-arrest populations.

    Time Period

    2026 - Present

    Location

    Stanford, CA, USA

    Organization

    Stanford University School of Medicine

  • M-Mode Versus Tissue Doppler-Derived TAPSE for Classification of Pulmonary Hypertension

    Comparison of M-mode and tissue Doppler-derived TAPSE for classifying pulmonary hypertension using CART analysis, quantile regression, and ROC comparisons across normal and pulmonary hypertension cohorts.

    Time Period

    2025 - Present

    Location

    Stanford, CA, USA

    Organization

    Stanford University School of Medicine

  • Echocardiographic Predictors of Vasoconstrictor Response in Hepatorenal Syndrome (HRS Harmony Consortium)

    Multi-center collaboration with Vanderbilt University and Virginia Commonwealth University harmonizing echocardiographic data to identify predictors of terlipressin and norepinephrine response in hepatorenal syndrome. Lead for the echocardiography and cirrhotic cardiomyopathy working group.

    Time Period

    2024 - Present

    Location

    Stanford, CA, USA

    Organization

    Stanford University School of Medicine

  • Left Ventricular Velocity-Time Integral as a Portable Measure of Stroke Volume (Project Baseline and WASE)

    Analysis of healthy-adult data from the Project Baseline cohort and the World Alliance Societies of Echocardiography (WASE) study, comparing linear and allometric scaling of LV VTI as a portable surrogate for stroke volume across body sizes.

    Time Period

    2024 - Present

    Location

    Stanford, CA, USA

    Organization

    Stanford University School of Medicine

Graduate and Fellowship Programs

All Publications

  • Not All Leg Swelling Is Volume Overload: Point-of-Care Ultrasound and Sirolimus-Associated Lymphedema After Combined Heart-Kidney Transplant. Clinical case reports Boyle, R., Patel, N. 2026; 14: e72717

    Abstract

    A 65-year-old man, one year post combined heart-kidney transplant, presented with acute kidney injury, dyspnea, and progressive leg edema unresponsive to escalating diuretics. Despite suspicion for volume overload, multi-organ point-of-care ultrasound (POCUS) revealed bilateral A-lines without B-lines or effusions, a small collapsible inferior vena cava, and preserved biventricular function, all inconsistent with cardiogenic congestion. The edema was attributed to sirolimus-associated lymphedema. Diuretic cessation and transition from sirolimus to everolimus improved renal function. This case illustrates the utility of integrated multi-organ POCUS in challenging assumptions about volume status and underscores the importance of contextualizing findings across multiple sonographic windows.

    View details for DOI 10.1002/ccr3.72717

    View details for PubMedID 42148354

    View details for PubMedCentralID PMC13175918

  • M-Mode Versus Tissue Doppler-Derived TAPSE for Classification of Pulmonary Hypertension Pulmonary Circulation Chen, R., Bagherzadeh, S., Patel, N., Khoury, P., Haddad, F. 2026: In press
  • Outcomes with inpatient use of midodrine in patients with heart failure and kidney failure on maintenance dialysis. Acta cardiologica Patel, N., Alvarez Concejo, B., Lo, K. B., Mishra, M., Kattubadi, A., Rangaswami, J. 2024: 1-4

    Abstract

    Midodrine, an FDA-approved medication for orthostatic hypotension, is also used off-label to manage hypotension in dialysis patients, including those with heart failure. However, in patients with reduced ejection fraction (HFrEF) and/or right heart failure, midodrine is potentially harmful. No known studies examine the safety of midodrine in hospitalised kidney failure patients with HF.The TriNetX database was queried for hospitalised kidney failure patients with HFrEF and/or right heart failure who experienced hypotension (SBP < 110 mm Hg or MAP < 70 mm Hg). Excluding those needing critical care or vasopressors, we compared cohorts based on midodrine use, matching for comorbidities.Analysis showed patients on midodrine had a higher 6-month mortality risk ratio (RR 1.53, 95% CI 1.037 to 2.246) and Hazard Ratio (HR 1.54, 95% CI 1.022 to 2.317) compared to those not on midodrine, indicating an association with increased mortality.This study illuminates the complexities in treating hospitalised patients with kidney failure and HF. Our findings, drawn from an exploratory analysis, indicate that inpatient midodrine use is associated with increased 6-month mortality. This may reflect deleterious effects from vasoconstriction and/or unmeasured confounders in this vulnerable population. This investigation, utilising TriNetX, was limited by access to deidentified aggregate data, preventing detailed exploration of specifics such as timing, dosage, and indications for midodrine use. Moreover, given its observational nature, cause-effect relationship cannot be established. Our findings indicate an increased mortality associated with midodrine use for hypotension, underscoring the need for further research and consideration of alternative strategies.

    View details for DOI 10.1080/00015385.2024.2365608

    View details for PubMedID 38860595

  • A subtle presentation of acute interstitial nephritis with a peculiar etiology. Clinical nephrology Adisa, O., Patel, N., Morisetti, P., Sulaiman, K. 2023; 100 (5): 240-242

    View details for DOI 10.5414/CN111215

    View details for PubMedID 37548466

  • Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study. International journal of cardiology Al-Yafeai, Z., Carvajal-González, A., Abduljabar, H., Arvas, M., Patel, S., Patel, N. 2022; 362: 153-157

    Abstract

    Emerging novel therapeutics have been developed to hamper the progression of multiple sclerosis (MS). However, the adverse events related to these new agents remain largely unknown. Therefore, we sought to investigate the cardiovascular complications of these drugs.Utilizing data from the U.S. food and drug administration (FDA) adverse events reporting system (FAERS), we comprehensively evaluated the cardiovascular complications of the newly FDA-approved anti-MS modifying therapies approved since 2015. Disproportionality signal analysis was conducted by measuring reporting odds ratio (ROR) with a 95% confidence interval of all cardiovascular adverse events since approval till 2021.After vetting the newly approved agents for MS, CD20 and CD25 inhibitors and sphingosine-1-phosphate receptors agonists were the latest approved medications for MS since 2015. Two CD20 (ocrelizumab, ofatumumab) and one CD25 inhibitors (daclizumab) were significantly associated with multiple cardiovascular adverse events. Among all the cardiotoxic events; coronary artery disease, cardiac failure and atrial fibrillation were the most predominant among CD20 or CD25 blockers. Interestingly, sphingosine-1-phosphate receptors (S1PR) agonists showed much fewer reported cardiac adverse events. However, fingolimod and siponimod were associated with significant AV block and bradycardia.Our data revealed the new MS agents are associated with various undefined cardiovascular complications. These findings potentially instigate further studies to personalize prescribing these agents for MS based on patient's cardiovascular profile.

    View details for DOI 10.1016/j.ijcard.2022.05.052

    View details for PubMedID 35643216

  • Aortic Stenosis Patients With Transcatheter Aortic Valve Replacement: Caution Recommended With Renal Failure During Hospitalization. Cureus Kaur, P., Ajibawo, T., Yomi, T., Patel, N., Baksh, M., Okotcha, E., Kataria, S., Patel, R. S. 2020; 12 (7): e9384

    Abstract

    Objective Our study aimed to assess the risk of in-patient mortality due to renal failure and other comorbidities in aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR). Methods We conducted a cross-sectional study using a Nationwide Inpatient Sample (NIS, January 2010 to December 2014) from the United States and included 33,325 patients with a primary diagnosis of AS. Logistic regression was used to evaluate the odds ratio (OR) for in-hospital mortality in AS by comorbidities including renal failure. Results The prevalence of renal failure in AS patients is 29.2%, and a higher proportion were males (60.1%) and non-white (14.1%). Major loss of function (96.6%) and in-hospital mortality (5.1%) were also proportionally higher in prevalence. Female patients (OR 1.35, 95% CI 1.20-1.51) had higher odds of in-patient mortality in AS patients. Race was a non-significant predictor for mortality risk. Patients with comorbid coagulopathy (OR 2.02, 95% CI 1.79-2.27) and heart failure (OR 1.62, 95% CI 1.39-1.89) have increased mortality in AS inpatients. After controlling confounders, renal failure was significantly associated with increased in-hospital mortality (OR 1.43, 95% CI 1.28-1.61) in AS patients. Conclusion Renal failure was prevalent in AS patients and was an independent factor that increases the risk of in-hospital mortality by 43%. Due to worse outcomes, more studies are required to evaluate risk-benefit ratio and strategies to improve health-related quality of life in post-TAVR patients with renal failure, and optimally decrease inpatient mortality.

    View details for DOI 10.7759/cureus.9384

    View details for PubMedID 32850251

    View details for PubMedCentralID PMC7445110

  • Clinical Perspective on 2019 Novel Coronavirus Pneumonia: A Systematic Review of Published Case Reports. Cureus Patel, R. S., Patel, N., Baksh, M., Zaidi, A., Patel, J. 2020; 12 (6): e8488

    Abstract

    The ongoing pandemic of 2019 novel coronavirus (2019-nCoV), which originated from Wuhan, China, has led to 68,279 deaths due to 2019-nCoV pneumonia as of May 5, 2020. We conducted a systematic review and included 16 case reports to summarize the transmission and pathology of 2019-nCoV, and clinical presentation, laboratory and imaging findings, and treatment in 2019-nCoV pneumonia. The disease is mild in most people; in some, it may progress to severe pneumonia with acute respiratory distress syndrome (ARDS). Patients with mild illness usually recover at home, with supportive care and isolation in accordance with guidelines. Patients who have moderate to severe pneumonia are usually monitored in the hospital. Although there is no definitive treatment for 2019-nCoV pneumonia so far, some antiviral drugs have shown promising results. The use of lopinavir/ritonavir and remdesivir was associated with significant clinical improvement in severe pneumonia. Nonetheless, we need more randomized clinical trials (RCTs) and treatment guidelines for developing effective management of the 2019-nCoV and improve patient outcomes by reducing mortality in high-risk patients. We also need more clinical trials and management guidelines for the effective management of 2019-nCoV pneumonia.

    View details for DOI 10.7759/cureus.8488

    View details for PubMedID 32656006

    View details for PubMedCentralID PMC7343316

  • Causative agents of urinary tract infections and their antimicrobial susceptibility patterns at a referral center in Western India: An audit to help clinicians prevent antibiotic misuse. Journal of family medicine and primary care Patel, H. B., Soni, S. T., Bhagyalaxmi, A., Patel, N. M. 2019; 8 (1): 154-159

    Abstract

    Urinary tract infections (UTIs) remain one of the most common infections in community and susceptibility of uropathogens to commonly used antimicrobials has declined over years. It is important to periodically study susceptibility patterns of uropathogens, so that empiric treatment can be determined using recent data, helping improve patient outcomes.Urine samples received by the laboratory for culture and susceptibility testing over a period of 3 months were analyzed and included in this study. Antimicrobial susceptibility testing was done on cultured isolates.Of total 3,151 urine samples received, 3,066 were processed, and organisms were isolated from 1,401 (45.69%) samples. Isolation rate from male and female urine samples was 45.29% and 46.32%, respectively. The most commonly isolated organism was Escherichia coli (36.11%), followed by Candida spp. (18.56%), and Klebsiella spp. (18.06%). E. coli was most susceptible to meropenem (91.89%) and imipenem (91.69%). Klebsiella spp. was most susceptible to imipenem(75.89%) and meropenem(75.49%). Susceptibility of E. coli and Klebsiella spp. to nitrofurantoin, cotrimoxazole, and ciprofloxacin was 72.33%, 32.02%, and 18.97%, and 51.77%, 27.27%, and 22.13%, respectively. Candida spp. was most susceptible to amphotericin B (97.30%).Treatment for UTIs should be determined based on current local antimicrobial susceptibility patterns of uropathogens to minimise therapeutic failures and prevent antibiotic misuse.

    View details for DOI 10.4103/jfmpc.jfmpc_203_18

    View details for PubMedID 30911498

    View details for PubMedCentralID PMC6396617

https://orcid.org/0000-0001-5040-6218